Glaukos outlines 2026 sales target of $600M-$620M as iDose TR and Epioxa drive growth momentum
Source: SeekingAlpha
2026-02-17 23:15:46 ET
More on Glaukos
- Glaukos Corporation (GKOS) Q4 2025 Earnings Call Transcript
- Glaukos Corporation (GKOS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Glaukos Corporation (GKOS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
- Glaukos Q4 2025 Earnings Preview
- Glaukos rises as FDA greenlights labeling update for iDose TR
Read the full article on Seeking Alpha
For further details see:
Glaukos outlines 2026 sales target of $600M–$620M as iDose TR and Epioxa drive growth momentum
Glaukos Corporation
NASDAQ: GKOS
GKOS Trading
-2.91% G/L:
$108.575 Last:
364,033 Volume:
$110 Open:
GKOS Latest News
GKOS Stock Data
$6,557,467,853
54,103,525
0.05%
122
N/A
Medical Equipment & Supplies
Healthcare
US
Aliso Viejo
